Cogesa and Croma Gio.Batta Merge, Unlocking 15% Growth and Accelerating Investments

Cogesa draws up a new plan with Croma Gio.Batta Iberia. The Galician health logistics company is starting a new roadmap after the merger with the Iberian subsidiary of the Italian company. According to Ángel Puente, honorary president of Croma Gio.Batta Iberia, the group is already being consulted about new projects abroad, while at the same time it does not rule out future acquisitions.

Following the merger last September, the new group’s total turnover exceeds thirty million euros. “We expect to continue growing at double digits over the next few years,” said Puente. The increase translates into a rise of more than 15% in its turnover.

With the merger, the Croma Gio.Batta Iberia group has become one of the largest providers of specialized services , with significant activity in the manufacturing of medical equipment and software in Spain.

The integration of Cogesa into the Italian company has strengthened the expansion plans of both companies. “The company’s potential is very large, not only because of its growth in Spain and Portugal, but also in other countries, from where we are already being asked for projects ,” the manager stresses.

Cogesa recently developed a traceability system for prostheses and implants

In addition to its international expansion, the company plans to continue expanding its business through acquisitions. “We do not rule out increasing our investments in the sector,” Puente admits.

In parallel, the healthcare logistics company is working on new projects with Artificial Intelligence (AI), something that, according to the executive, “foreshadows a very promising future for the group.”

The Croma Gio.Batta Iberia group offers healthcare logistics services through the management of plant warehouses, general warehouses and integrated logistics platforms ; biomedical logistics (blood, bone marrow, corneas, skin, bone, etc.); software development for the control of medical material, as well as prostheses and implants; traceability of biomedical logistics.

The company also specializes in the repair, manufacturing and sale of surgical instruments, as well as in the design of projects and construction of sterilization units and operating rooms for healthcare centers and hospitals, among other services.

Croma Gio.Batta has been operating in Spain since 2012 and years later expanded to Portugal, creating the Iberian subsidiary

Founded in Italy in 1935, the multinational Croma Gio.Batta has been diversifying its activity from the sale and management of surgical instruments and medical devices, to the design of projects and construction of sterilization units and operating rooms for health centers and hospitals, or the provision of high quality and specialized health services.

The company arrived in Spain in 2012 and currently provides sterilization services in a dozen public hospitals in the Community of Madrid, including large centers such as the La Paz University Hospital, the 12 de Octubre University Hospital or the San Carlos Clinical Hospital, as well as the Burgos Hospital.

Cogesa, for its part, has more than thirty years of experience in the healthcare sector, providing logistics services from purchasing management, reception, storage, distribution of material, to warehouse management at the point of consumption, decision-making on stocks and monthly sending of reports and dashboards to its clients. In addition, the company is a pioneer in Spain in biomedical logistics, with the transport and management of biological products at controlled temperatures.

Before the merger with Croma Gio.Botta, Cogesa developed new software for traceability of prostheses and implants . The new system is integrated with stock control such as cabinets or rooms with RFID technology and with the electronic medical record, guaranteeing safe and efficient data management.

__

(Featured image by Marco Bianchetti via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us